The company announced that it has been granted patent covering “Substituted Ethylamine Fused Heterocyclic Mescaline Derivatives.”
Collaboration to leverage AbbVie's psychiatry expertise and Gilgamesh's innovative research platform to develop next-generation neuroplastogens for the treatment of psychiatric disorders
Agreement builds on 15 years of successful collaboration between AbbVie and Richter, including globally launched cariprazine products
Rivotril is the innovator/ reference brand of clonazepam and is widely prescribed for the management of neurological and psychiatric conditions
If approved, TEV-'749 could help address a significant unmet need in available schizophrenia treatment options by addressing the lack of viable long-acting olanzapine formulations
Despite some promising subgroup signals, the company indicated it will not pursue further psychiatric trials
TMS offers new hope to patients suffering from stroke, migraine, neuropathic pain, depression, and other disorders
The company is excluding data from the affected sites to maintain the study's integrity
This marks Lupin’s first commercial product leveraging PrecisionSphere, a proprietary long-acting injectable (LAI) technology
The results demonstrated meaningful reductions in the severity of involuntary movements and notable improvements in patient-reported quality of life
Subscribe To Our Newsletter & Stay Updated
